Who is sponsoring NCT05055999?

NCT05055999 is sponsored by Hunan Province Tumor Hospital.

What drugs are being tested in NCT05055999?

Interventions in NCT05055999: First line EC/EP+Atezolizumab.

What condition does NCT05055999 study?

NCT05055999 studies Extensive Stage Small Cell Lung Cancer.

Is NCT05055999 still recruiting?

NCT05055999 is currently completed. Last updated 25 January 2022.

Last reviewed 2022-01-25 · How we verify

NCT05055999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Completed Last updated 25 January 2022

What this trial tests

trial testing First line EC/EP+Atezolizumab in Extensive Stage Small Cell Lung Cancer in 60 participants. Completed in 1 September 2021.

Timeline

1 April 2019

Primary endpoint
1 July 2021

1 September 2021

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 April 2019
Primary completion	1 July 2021
Estimated completion	1 September 2021
Sites	1 location across China

Drugs / interventions tested

First line EC/EP+Atezolizumab — full drug profile →

Conditions studied

Extensive Stage Small Cell Lung Cancer — all drugs for Extensive Stage Small Cell Lung Cancer →

Sponsor

Hunan Province Tumor Hospital

Who can join

18 and older, any sex, with Extensive Stage Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis.
Nallasamy P, Nimmakayala RK, Parte S, Are AC, et al · · 2022 · cited 163× · PMID 36550571 · DOI 10.1186/s12943-022-01682-x
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.
Rodríguez-Lara A, Rueda-Robles A, Sáez-Lara MJ, Plaza-Diaz J, et al · · 2023 · cited 15× · PMID 37513787 · DOI 10.3390/pathogens12070940
Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.
Arandhara A, Bhuyan P, Das BK. · · 2025 · cited 7× · PMID 39934547 · DOI 10.1007/s12672-025-01902-y

Verify or expand the search:

Other trials of First line EC/EP+Atezolizumab

Trials testing the same drug.

NCT05055947 — Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer · completed

Other recruiting trials for Extensive Stage Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07107490 — A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER · Phase 1 · recruiting
NCT07037758 — A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311 · Phase 1 · recruiting
NCT06598306 — Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) · Phase 1 · recruiting
NCT06502977 — Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines o · Phase 2 · active not recruiting
NCT05468489 — To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC · Phase 3 · active not recruiting

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05055999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 25 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing